No abstract available.
Chimera*

Anti-f(ce) has been associated with hemolytic transfusion reaction (HTR) and hemolytic disease of the fetus and newborn (HDFN), however, anti-Cs(a) has not been associated with red blood cell (RBC) destruction. Although anti-Cs(a) has clinical insignificance as a high-titer low-avidity (HTLA) antibody, this antibody can cause confusion in interpreting an antibody identification test, particularly coexistence of a clinically significant antibody. A 65-year-old woman with liver metastases of Klatskin tumors and cholangitis was admitted to the hospital for abdominal pain. She developed hematochezia on hospital day 10. She was at the status of active bleeding and required transfusion. The result of antibody identification test was warm-reactive autoantibody and unidentifiable alloantibody, therefore, the least incompatible packed RBCs had to be transfused to the patient. No hemolytic transfusion reaction occurred and hemoglobin level was normalized. Thereafter, anti-f(ce) and anti-Cs(a) antibodies were identified in the patient's serum. To the best of our knowledge, this is the first report of anti-f and anti-Cs(a) antibodies in Korea.
Abdominal Pain ; Aged ; Antibodies* ; Blood Group Incompatibility ; Cholangitis ; Erythrocytes ; Female ; Fetus ; Gastrointestinal Hemorrhage ; Hemorrhage ; Humans ; Infant, Newborn ; Klatskin's Tumor ; Korea ; Liver ; Neoplasm Metastasis

Kidney is rarely an involved organ of graft-versus-host disease (GVHD). Here, we report on a case of membranous nephropathy and interstitial nephritis after allogenic hematopoietic stem cell transplantation (HSCT) in a 44-year-old female patient with acute lymphoblastic leukemia. The patient received GVHD prophylaxis with low dose steroid, cyclosporin, and short course methotrexate. Cyclosporine was tapered out 17 months after allogeneic HSCT. Thereafter, the patient developed kidney impairment and nephrotic range proteinuria. Kidney biopsy revealed membranous nephropathy concurrent with interstitial nephritis.
Adult ; Biopsy ; Cyclosporine ; Female ; Glomerulonephritis, Membranous* ; Graft vs Host Disease ; Hematopoietic Stem Cell Transplantation* ; Humans ; Kidney ; Methotrexate ; Nephritis, Interstitial* ; Precursor Cell Lymphoblastic Leukemia-Lymphoma* ; Proteinuria

BACKGROUND: Platelet antigen and antibody tests have been used in platelet immunological disorders, such as neonatal alloimmune thrombocytopenia (NAIT) and post-transfusion purpura (PTP). Mixed passive hemagglutination (MPHA) method has several advantages, including frozen preservation of platelets, ability to differentiate between anti-HLA and platelet-specific antibodies, and quick and easy interpretation without expensive equipment. In this study, we intended to develop the MPHA method using indicator cells of anti-Rh(D) sensitized group O, Rh+ RBCs. METHODS: We made indicator cells sensitized with anti-Rh(D) with various strengths (1:32 to 1:256) and determined the optimal strength. We determined the sensitivity of the MPHA and compared the results using flow cytometry. We observed the changes of the reaction according to the storage time of indicator cells. RESULTS: The optimal sensitization strengths of the indicator cells were 1:192 and 1:256. MPHA showed strong positive results with 1:8,192 diluted positive control, while the detection limit of flow cytometry was 1:128. Until the second week (mean 16 days), the indicator cells showed good results comparable to those of fresh ones. CONCLUSION: We developed the MPHA method using indicator cells of anti-Rh(D) sensitized group O, Rh+ RBCs. We produced the indicator cells in our own laboratory and obtained platelet panels with rare antigen typing using frozen-stored platelets. This technology will be used effectively for detection of platelet antigens and identification of platelet antibodies and also for platelet crossmatching.
Antibodies ; Blood Platelets* ; Flow Cytometry ; Hemagglutination* ; Limit of Detection ; Purpura ; Thrombocytopenia, Neonatal Alloimmune

BACKGROUND: Therapeutic leukapheresis is the cytoreduction procedure performed before chemotherapy in patients with hyperleukocytosis for prevention of complication. However, there have been clinical concerns about bleeding tendency due to anticoagulant used during the procedure. The aim of our study was to compare the clinical characteristics and hematological parameters before and after therapeutic leukapheresis in order to evaluate its effect on bleeding tendency and to provide a guideline for treatment strategy. METHODS: The clinical data for 39 procedures of therapeutic leukapheresis performed on 17 patients with hyperleukocytosis from May 2005 to October 2013 at the National Cancer Center were reviewed retrospectively. RESULTS: The patients consisted of 11 males and six females. The mean age was 41 years old (range, 8~74). The mean number of therapeutic leukapheresis per patient was two (range, 1~4). Clinical symptoms improved in 14 patients (82%) after therapeutic leukapheresis and three patients (18%) were not yet to improve. The mean WBC count was significantly reduced by 32.6% (+/-17.4) after therapeutic leukapheresis, from 250,146/microL (+/-117,000) to 174,702/microL (+/-104,700) (P<0.001). The mean volume of single removal was 298 ml with 4.25x10(11)/L (+/-1.54) WBCs. After therapeutic leukapheresis, the mean platelet count showed a decline from 85x10(9)/L (+/-43) to 71x10(9)/L (+/-26). However, the prothrombin time (PT) and activated partial thromboplastin time (aPTT) did not show a significant increase (PT, P=0.637; aPTT, P=0.054). CONCLUSION: Therapeutic leukapheresis is demonstrated as an effective and safe treatment that can improve symptoms and reduce leukocytes in hyperleukocytosis.
Drug Therapy ; Female ; Hemorrhage ; Humans ; Leukapheresis* ; Leukocytes ; Leukostasis ; Male ; Partial Thromboplastin Time ; Platelet Count ; Prothrombin Time ; Retrospective Studies

BACKGROUND: Massive transfusion (MT) is an unusual event and has been defined as replacement of total body fluid volume in less 24 hours or transfusion of 10 or more RBC units in 24 hours. MT is a high priority treatment for major blood loss. METHODS: We gathered 78 patients receiving MT from 2008 to 2013 at Severance hospital using electronic medical records and performed a retrospective review. For each case, we analyzed patients' characteristics, including sex, age, major causes of MT, and clinical outcome. We also calculated the ratio of each blood component transfused. RESULTS: Patient sex ratio of male and female was 1.60 and percentage of patients over age 40 was 58.4%. The individual diagnostic categories were 28.2% of cardiovascular surgery, 26.9% of liver transplantation, 11.5% of upper gastrointestinal bleeding, and 5.2% of trauma. The overall mortality rate was 47.3%. Mortality rate ranged from the lowest (52.3%) for liver transplantation to the highest (77.8%) for upper gastrointestinal tract bleeding. No correlation was observed between causes of MT and mortality rate. The average usage of FFP: RBC and platelet: RBC ratio was 0.83 and 0.68, respectively. However, recently, the ratio of two components transfused is close to 1.0. CONCLUSION: The highest priority in MT was rapidity and propriety for improvement of patient survival. By regularly reviewing MT cases, we could provide an improved massive transfusion service.
Blood Platelets ; Blood Transfusion* ; Body Fluids ; Electronic Health Records ; Female ; Hemorrhage ; Humans ; Liver Transplantation ; Male ; Mortality ; Retrospective Studies ; Sex Ratio ; Tertiary Care Centers* ; Upper Gastrointestinal Tract

BACKGROUND: The distribution of ABO and Rhesus D (RhD) blood group antigens differs according to race and region. Previous studies have reported that blood group type was associated with not only transfusion-related diseases but also various diseases, such as malignancy and infectious disease. However, true relationship of blood groups and many diseases remained controversial. The aim of this study was to determine whether ABO and RhD blood groups are correlated with several infectious diseases. METHODS: From January 2003 to December 2012, we retrospectively reviewed results for HBsAg, HCV Ab, HIV Ab, VDRL, HAV IgM, CMV IgM, EBV VCA IgM, and Clostridium difficile toxin A and B (CD toxin). We also reviewed ABO and RhD results of these patients. Data were analyzed using chi-square test and binary logistic regression test. Odds ratio and 95% confidence intervals were determined. RESULTS: A total of 109,898 medical records of ABO and HBsAg results were reviewed. Blood group type-A was more prone to have positive results with HBsAg, while blood group type-O was less affected (odds ratio 1.086, P=0.003, odds ratio 0.935, P=0.029, respectively). With 3,171 records of CD toxin, blood group type-O was more affected (odds ratio 1.247, P=0.027). The relationship of the other serologic results and blood groups was not statistically significant. CONCLUSION: Seroprevalence of HBsAg and CD toxin showed an association with blood group type. Blood group type-A had higher HBsAg seroprevalence than the other group. Blood group type-O was more prone to have CD toxin.
Blood Group Antigens ; Clostridium difficile ; Communicable Diseases* ; Continental Population Groups ; Hepatitis B Surface Antigens ; Herpesvirus 4, Human ; HIV ; Humans ; Immunoglobulin M ; Korea ; Logistic Models ; Medical Records ; Odds Ratio ; Phenotype* ; Retrospective Studies ; Seroepidemiologic Studies*

BACKGROUND: In Korea, since 1990, in an effort to reduce the transmission of non-A, non-B hepatitis, all blood donations with alanine aminotransferase (ALT) levels above 65 IU/L are discarded. In 2012, 64.8% of the disposed blood units at the Korean Red Cross blood centers were due to high ALT levels. Pre-donation ALT testing might prevent unnecessary blood donation and save related expenses. We evaluated performance of point-of-care test (POCT) devices for pre-donation ALT screening. METHODS: ALT levels by four ALT POCT devices (Mission C100, Acon; Reflotron Plus, Roche; Labgeo PT10, Samsung; and FDC NX500, Fujifilm) were compared with venous blood results using laboratory chemistry analyzers (AU series, Beckman Coulter Inc.). Intraclass correlation coefficients (ICCs), sensitivity (ability to detect ALT > or =65 IU/L), and specificity (ability to detect <65 IU/L) for each method were calculated. RESULTS: Compared with the laboratory analyzers, the ICCs of ALT measurements by Mission C-100, Reflotron Plus, Labgeo PT10, and FDC NX500 were 0.96 (95% confidence interval (CI): 0.95~0.97), 0.99 (95% CI: 0.99~0.99), 0.98 (95% CI: 0.98~0.98), and 0.94 (95% CI: 0.91~0.96), respectively. The sensitivity was 80.95% for Mission C-100, 83.33% for Reflotron Plus, 78.57% for Labgeo PT10, and 97.62% for FDC NX500. The specificity was 99.13% for Mission C-100, 100.00% for Reflotron Plus, 99.78% for Labgeo PT10, and 98.26% for FDC NX500. CONCLUSION: The ALT POCT devices showed almost perfect agreement with the laboratory analyzers and could be useful for pre-donation ALT screening. However, before implementing ALT POCT devices, cost-effectiveness analyses should be performed.
Alanine Transaminase* ; Blood Donors ; Chemistry ; Hepatitis ; Humans ; Korea ; Mass Screening ; Missions and Missionaries ; Red Cross ; Sensitivity and Specificity

BACKGROUND: Fresh frozen plasmas (FFPs) do not seem to be effectively managed compared to red blood cells and prophylactic transfusions of FFPs still occur in many cases. We evaluated appropriateness of FFP transfusion and analyzed the conditions of FFP usage in a regional hospital. METHODS: The conditions of FFP usage were investigated over one year from January 2012 to December 2012 using computerized medical records and archived documents. Results of coagulation tests before transfusion, appropriateness of FFP usage, and the reason for discarding FFP were investigated, and the assessment of the appropriateness of FFP transfusion was based on the transfusion guidelines published by the Korea Centers for Disease Control and Prevention. RESULTS: During the study period, 2,675 units of FFP were transfused to 364 patients over 752 episodes. FFP transfusions were inappropriate in 33.1% of episodes, and empirically used FFPs without performing pre-transfusion coagulation tests or when the test results were in the reference range occupied 25.7% of inappropriate FFP transfusions. Improper use of FFPs was most common in the Department of Emergency Medicine. During the three-year period, discarding rate of FFPs was 1.3% and the most common cause was the death or worsening condition of patients. Discarding FFPs was greatest in the Department of Thoracic Surgery and Cardiology. CONCLUSION: Many FFPs were inappropriately transfused. This was due to a general lack of understanding of the transfusion guidelines among physicians. Continuous training and education as well as ongoing monitoring of FFP usage are necessary.
Cardiology ; Centers for Disease Control and Prevention (U.S.) ; Education ; Emergency Medicine ; Erythrocytes ; Humans ; Korea ; Medical Records Systems, Computerized ; Plasma* ; Reference Values ; Thoracic Surgery

BACKGROUND: The automation system for blood typing and antibody screening has been developed and is now used widely. In this study, we evaluated the economic effectiveness between automation system QWALYS-3 (DIAGAST, Loos Cedex, France) and manual testing. METHODS: Clinical samples from March 2012 were used for comparison of the costs and TAT for ABO-RhD blood typing and antibody screening. The costs included those of materials (reagents and consumables), labor, and equipment depreciation. TAT was analyzed for either blood typing only for one, 16, and 32 samples or blood typing and antibody screening for the same number of samples. RESULTS: The blood typing TAT for one, 16, and 32 samples was 4.5, 35.1, and 70.1 minutes by manual and 24.0, 36.0, and 38.1 minutes by automated system. Both blood typing and antibody screening TAT for one, 16, and 32 samples was 27.5, 75.0, and 129.9 minutes by manual and 45.0, 52.0, and 54.0 minutes by automation. CONCLUSION: The blood automation system reduced TAT only for the batch test, therefore, when using the automation system, blood bank test size and emergency situation should be considered.
Automation* ; Blood Banks* ; Blood Grouping and Crossmatching* ; Depreciation ; Emergencies ; Mass Screening*